الفهرس 
CHRONIC MYELOID LEUKEMIA (CML)Only 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
the cause of chronic myeloid leukemia is a
constitutively active BCR-ABL tyrosine kinase , It is a very
rare disease in children, BMT is still the only curative therapy
but TKI developed a new era in CML management. Subject
and methods: this study was conducted on 98 children and
adolescents diagnosed as CML during the period between
January 1995 to December 2005 , in the Pediatric Hematology
/ Oncology Unit , Children Hospital , Ain Shams University ,
National Cancer Institute and Nasser Institute. We recorded
the epidemiological features of the disease, symptoms,
physical signs, peripheral blood and BM analysis at initial
diagnosis, follow up patients till December 2008 was done,
comparison between different TTT modalities was performed
regarding OS,CHR,CR, duration till remission, duration till
blast crisis, tolerance to therapy and outcome. Results: there
was male preponderance with a ratio about 2:1 ,CML still
extremely rare in very young children, >58% of patients were
older than 10 years at diagnosis, an incidental diagnosis was
made in 23.4% of patients with lower TLC and higher HB%
than symptomatic group, about 6.1% of patients diagnosed in
accelerated phase, 11.2% in blast crisis, the most common
symptoms were athenia and symptoms related to splenomegaly
,imatinib and BMT were superior to other TTT modalities,
imatinib was superior to BMT regarding outcome and toxicity
profile. Conclusion: imatinib has to be regarded as standard of
care first line TTT in pediatric CML but the long term
outcome can not yet be assessed. On the other hand alloSCT
holds the promise of cure but with definite toxicity and
mortality.